^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mediastinal B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the panel deems the inclusion of rituximab in the treatment of this patient population to be appropriate.
